Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders

Publication date: August 2018
Source:Biomedicine & Pharmacotherapy, Volume 104
Author(s): Priscila Lúcia Pawloski, Camila Guimarães Moreira, Cintia Delai Silva Horinouchi, Daniel Fernandes, Luiz Renato Olchanheski, Willian Machado, Daniela Almeida Cabrini, Michele Dietrich, Kátia Paludo, Michel Fleith Otuki
Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes related to psoriasis pathogenesis, such as inflammation and cell proliferation. The aim of this study was to investigate the influence of renin inhibition on inflammation parameters and keratinocyte proliferation in a mouse model of chronic skin inflammation induced by croton oil. Aliskiren had anti-inflammatory effects by reducing levels of tumor necrosis factor-α and interleukin -6, and by inhibiting myeloperoxidase activity. Aliskiren also showed antiproliferative activity by reducing epidermal hyperplasia and proliferating cell nuclear antigen levels. Aliskiren treatment did not induce alterations in the cardiovascular system, normal skin thickness, and organ weight. These results suggest that aliskiren could be a valuable tool to be incorporated in the treatment of hyperproliferative and inflammatory skin disorders such as psoriasis.



https://ift.tt/2rH3mga